1. Home
  2. IOVA vs PTY Comparison

IOVA vs PTY Comparison

Compare IOVA & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • PTY
  • Stock Information
  • Founded
  • IOVA 2007
  • PTY 2002
  • Country
  • IOVA United States
  • PTY United States
  • Employees
  • IOVA N/A
  • PTY N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • PTY Investment Managers
  • Sector
  • IOVA Health Care
  • PTY Finance
  • Exchange
  • IOVA Nasdaq
  • PTY Nasdaq
  • Market Cap
  • IOVA 2.6B
  • PTY 2.2B
  • IPO Year
  • IOVA N/A
  • PTY N/A
  • Fundamental
  • Price
  • IOVA $5.91
  • PTY $14.41
  • Analyst Decision
  • IOVA Strong Buy
  • PTY
  • Analyst Count
  • IOVA 9
  • PTY 0
  • Target Price
  • IOVA $23.33
  • PTY N/A
  • AVG Volume (30 Days)
  • IOVA 9.1M
  • PTY 550.4K
  • Earning Date
  • IOVA 02-26-2025
  • PTY 01-01-0001
  • Dividend Yield
  • IOVA N/A
  • PTY 9.65%
  • EPS Growth
  • IOVA N/A
  • PTY N/A
  • EPS
  • IOVA N/A
  • PTY N/A
  • Revenue
  • IOVA $90,858,000.00
  • PTY N/A
  • Revenue This Year
  • IOVA $13,758.71
  • PTY N/A
  • Revenue Next Year
  • IOVA $171.20
  • PTY N/A
  • P/E Ratio
  • IOVA N/A
  • PTY N/A
  • Revenue Growth
  • IOVA 12751.20
  • PTY N/A
  • 52 Week Low
  • IOVA $5.62
  • PTY $11.92
  • 52 Week High
  • IOVA $18.33
  • PTY $14.88
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 28.87
  • PTY 46.72
  • Support Level
  • IOVA $5.62
  • PTY $14.22
  • Resistance Level
  • IOVA $6.44
  • PTY $14.45
  • Average True Range (ATR)
  • IOVA 0.45
  • PTY 0.09
  • MACD
  • IOVA -0.10
  • PTY 0.01
  • Stochastic Oscillator
  • IOVA 11.46
  • PTY 80.43

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

Share on Social Networks: